Add Formweb to your mobile device
Brand name products with an equivalent generic may not be available to order at Henry Ford Health. For questions, contact inpatient pharmacy.
Search results for:
denosumab
denosumab
| Drug Name | Form | Strength | Ambulatory Use Only | Ambulatory Restrictions | Inpatient Restrictions | Non-Formulary |
|---|---|---|---|---|---|---|
| Conexxence | SOLUTION, SUBCUTANEOUS | 60 mg/mL | ||||
| Jubbonti | SOLUTION, SUBCUTANEOUS | 60 mg/mL | ||||
| Prolia | SOLUTION, SUBCUTANEOUS | 60 mg/mL | ||||
| Stoboclo | SOLUTION, SUBCUTANEOUS | 60 mg/mL | ||||
| Bomyntra | SOLUTION, SUBCUTANEOUS | 120 mg/1.7 mL | ||||
| Osenvelt | SOLUTION, SUBCUTANEOUS | 120 mg/1.7 mL | ||||
| Wyost | SOLUTION, SUBCUTANEOUS | 120 mg/1.7 mL | ||||
| Xgeva | SOLUTION, SUBCUTANEOUS | 120 mg/1.7 mL |
VIEW MORE metabolic agents, bone resorption inhibitors, miscellaneous bone resorption inhibitors
CLASS
CLASS
m00358, m00409, m00415
| Prolia | Generic Name | Brand Name |
| Biosimilar (HFH preferred) | denosumab-bnht | Conexxence |
| Biosimilar (approved alternate) | denosumab-bbdz | Jubbonti |
| Biosimilar (approved alternate) | denosumab-bmwo | Stoboclo |
| Originator product | denosumab | Prolia |
| Xgeva | Generic Name | Brand Name |
| Biosimilar (HFH preferred) | denosumab-bnht | Bomyntra |
| Biosimilar (approved alternate) | denosumab-bmwo | Osenvelt |
| Biosimilar (approved alternate) | denosumab-bbdz | Wyost |
| Originator product | denosumab | Xgeva |
Last updated: Dec. 11, 2025
- Biosimilar Use of Biosimilars at Henry Ford Health
- Black Box Warning Prolia - Severe Hypocalcemia in Patients with Advanced Kidney Disease
- REMS View FDA REMS Info